IL10 and inflammatory bowel disease: Consistent with the in vivo findings, in vitro experiments revealed that serum containing the Xianhecao-Huanglian drug pair reduced the levels of TNF-α, IL-1β, and IL-6 while boosting IL-10 secretion in the LPS-induced IBD inflammatory cell model.